Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1988 1
1990 1
1991 1
1992 2
1993 2
1994 4
1995 2
1996 3
1998 2
1999 6
2000 4
2001 8
2002 7
2003 11
2004 12
2005 16
2006 16
2007 15
2008 17
2009 12
2010 16
2011 16
2012 13
2013 20
2014 13
2015 8
2016 15
2017 12
2018 11
2019 13
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

277 results
Results by year
Filters applied: . Clear all
Page 1
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Angeles Ramos DM, Maurer HC, Olive KP, Coussens LM, Morgan TK, Marks DL. Michaelis KA, et al. Among authors: marks dl. Nat Commun. 2019 Oct 15;10(1):4682. doi: 10.1038/s41467-019-12657-w. Nat Commun. 2019. PMID: 31615993 Free PMC article.
Establishment and characterization of a novel murine model of pancreatic cancer cachexia.
Michaelis KA, Zhu X, Burfeind KG, Krasnow SM, Levasseur PR, Morgan TK, Marks DL. Michaelis KA, et al. Among authors: marks dl. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):824-838. doi: 10.1002/jcsm.12225. Epub 2017 Jul 20. J Cachexia Sarcopenia Muscle. 2017. PMID: 28730707 Free PMC article.
Pretreatment Cancer-Related Cognitive Impairment-Mechanisms and Outlook.
Olson B, Marks DL. Olson B, et al. Among authors: marks dl. Cancers (Basel). 2019 May 16;11(5):687. doi: 10.3390/cancers11050687. Cancers (Basel). 2019. PMID: 31100985 Free PMC article. Review.
An Insulin-Responsive Sensor in the SIRT1 Disordered Region Binds DBC1 and PACS-2 to Control Enzyme Activity.
Krzysiak TC, Thomas L, Choi YJ, Auclair S, Qian Y, Luan S, Krasnow SM, Thomas LL, Koharudin LMI, Benos PV, Marks DL, Gronenborn AM, Thomas G. Krzysiak TC, et al. Among authors: marks dl. Mol Cell. 2018 Dec 20;72(6):985-998.e7. doi: 10.1016/j.molcel.2018.10.007. Epub 2018 Nov 8. Mol Cell. 2018. PMID: 30415949 Free PMC article.
A TLR/AKT/FoxO3 immune tolerance-like pathway disrupts the repair capacity of oligodendrocyte progenitors.
Srivastava T, Diba P, Dean JM, Banine F, Shaver D, Hagen M, Gong X, Su W, Emery B, Marks DL, Harris EN, Baggenstoss B, Weigel PH, Sherman LS, Back SA. Srivastava T, et al. Among authors: marks dl. J Clin Invest. 2018 May 1;128(5):2025-2041. doi: 10.1172/JCI94158. Epub 2018 Apr 16. J Clin Invest. 2018. PMID: 29664021 Free PMC article.
Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance.
Michaelis KA, Norgard MA, Levasseur PR, Olson B, Burfeind KG, Buenafe AC, Zhu X, Jeng S, McWeeney SK, Marks DL. Michaelis KA, et al. Among authors: marks dl. Brain Behav Immun. 2019 Nov;82:338-353. doi: 10.1016/j.bbi.2019.09.004. Epub 2019 Sep 6. Brain Behav Immun. 2019. PMID: 31499172 Free article.
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche.
Abdelhamed S, Butler JT, Doron B, Halse A, Nemecek E, Wilmarth PA, Marks DL, Chang BH, Horton T, Kurre P. Abdelhamed S, et al. Among authors: marks dl. EMBO Rep. 2019 Jul;20(7):e47546. doi: 10.15252/embr.201847546. Epub 2019 Jun 17. EMBO Rep. 2019. PMID: 31267709 Free PMC article.
TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia.
Burfeind KG, Zhu X, Levasseur PR, Michaelis KA, Norgard MA, Marks DL. Burfeind KG, et al. Among authors: marks dl. Brain Behav Immun. 2018 Oct;73:364-374. doi: 10.1016/j.bbi.2018.05.021. Epub 2018 May 28. Brain Behav Immun. 2018. PMID: 29852290 Free PMC article.
Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Ramos DMA, Maurer HC, Olive KP, Coussens LM, Morgan TK, Marks DL. Michaelis KA, et al. Among authors: marks dl. Nat Commun. 2019 Nov 15;10(1):5257. doi: 10.1038/s41467-019-13151-z. Nat Commun. 2019. PMID: 31729370 Free PMC article.
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. McCleary-Wheeler AL, et al. Among authors: marks dl. Pancreatology. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21. Pancreatology. 2020. PMID: 31787526 Free PMC article.
277 results
Jump to page
Feedback